Related Experiment Video
Updated: Mar 10, 2026

Full-root Aortic Valve Replacement by Stentless Aortic Xenografts in Patients with Small Aortic Roots
Published on: May 21, 2017
Anticoagulation After Biological Aortic Valve Replacement: Is There An Optimal Regimen?
Tamer Owais1, Mina Rouman1, Martin Breuer1
1Department of Cardiac Surgery and Cardiology, Central Clinic of Bad Berka, Germany.
Insights
For biological aortic valve replacement (BAVR), aspirin showed lower bleeding risk and similar survival compared to warfarin. Aspirin is a safer alternative for early postoperative anticoagulation after BAVR.
Area of Science:
- Cardiology
- Cardiovascular Surgery
- Pharmacology
Background:
- Anticoagulation after biological heart valve replacement is debated due to thrombosis risks.
- Guidelines recommend warfarin post-biological aortic valve replacement (BAVR), but evidence is debated.
- Current guidelines lack clear risk-benefit data for early anticoagulation post-BAVR.
Purpose of the Study:
- To compare aspirin and warfarin efficacy in patients post-BAVR.
- To evaluate bleeding, ischemic events, and survival rates.
- To determine optimal anticoagulation strategy in the early postoperative phase.
Main Methods:
- 863 patients undergoing BAVR were randomized into two groups.
- One group received warfarin (n=430), the other aspirin (n=433) for three months.
- Primary endpoints included bleeding, cerebral ischemic events, and survival.
Main Results:
- Aspirin showed a statistically lower risk of postoperative bleeding.
- Cerebral ischemic events were comparable between groups in the short term.
- No significant differences in stroke-free or overall survival were observed.
Conclusions:
- Warfarin anticoagulation is statistically inferior to aspirin for bleeding risk post-BAVR.
- Aspirin demonstrates comparable efficacy and improved safety over warfarin.
- Platelet inhibition with aspirin is a potentially safer early anticoagulation strategy post-BAVR.
Background:
The anticoagulation of biological heart valves remains a 'hot spot' of discussion in various domains due to the risk of developing valve thrombosis and arterial thromboembolism. The situation has always been controversial, especially during the early postoperative phase. The American College of Cardiology/ American Heart Association and European Society of Cardiology guidelines recommend the use of warfarin for the first three months after biological aortic valve replacement (BAVR), although the American College of Chest Physicians guidelines suggest that these recommendations are experience-based and that the risk/benefit is unclear. The aim of the present study was to compare the efficacy of aspirin and warfarin in patients after BAVR.
Methods:
A total of 863 patients who underwent BAVR between 2008 and 2015 was allocated to two groups. Each group was managed with a specific anticoagulation regimen, with 430 patients receiving warfarin during the first three postoperative months, and 433 receiving aspirin. The major study end points were bleeding, cerebral ischemic events, and survival.
Results:
In total, 10 and 15 postoperative cerebral ischemic events occurred between 24 h and three months after surgery in patients treated with aspirin and warfarin, respectively. After three months the incidence of cerebral ischemic events did not differ greatly between the two groups. The rate of major bleeding events and rates of stroke-free survival and overall survival were not statistically significant between the warfarin and aspirin groups.
Conclusions:
Plasma anticoagulation with warfarin during the early postoperative phase was shown statistically to be inferior to platelet aggregation inhibition by aspirin with regards to postoperative bleeding risk, cerebral ischemic events, and survival.
More Related Videos
Related Concept Videos
Aortic Regurgitation III: Medical Management
Aneurysm IV: Nursing Management
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Aortic Regurgitation I: Introduction
Aneurysm III: Interprofessional Care

